COVID-19 vaccine safety monitoring in the Republic of Korea: February 26, 2021 to April 30, 2021 [PDF]
Osong Public Health and Research Perspectives, 2021Objectives On February 26, 2021, coronavirus disease 2019 (COVID-19) vaccination was started for high-priority groups based on the recommendation of the Advisory Committee on Immunization Practices with 2 available COVID-19 vaccines (AstraZeneca and ...
Hyun-kyung Oh+6 more
doaj +1 more source
COVID-19 vaccine safety monitoring in Republic of Korea from February 26, 2021 to October 31, 2021 [PDF]
Osong Public Health and Research Perspectives, 2021Objectives This study aimed to present data on reported adverse events following coronavirus disease 2019 (COVID-19) vaccination in Republic of Korea from February 26 to October 31, 2021, and to determine whether any significant patterns emerged from an ...
Insob Hwang+4 more
doaj +1 more source
Self-reported adverse events after 2 doses of COVID-19 vaccine in Korea [PDF]
Epidemiology and Health, 2022OBJECTIVES In Korea, a national coronavirus disease 2019 (COVID-19) vaccination program was implemented, including 4 vaccines against COVID-19. A text messaging-based survey, in addition to a passive adverse event reporting system, was launched to ...
Yunhyung Kwon+7 more
doaj +1 more source
Adverse events of the Pfizer-BioNTech COVID-19 vaccine in Korean children and adolescents aged 5 to 17 years [PDF]
Osong Public Health and Research Perspectives, 2022Objectives This study aimed to identify potential safety signals and adverse events following the primary Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccination series among children and adolescents aged 5 to 17 years in the Republic of Korea ...
Seontae Kim+5 more
doaj +1 more source
Safety monitoring of COVID-19 vaccines: February 26, 2021, To June 4, 2022, Republic of Korea [PDF]
Clinical and Experimental Pediatrics, 2023As of June 2022, 5 coronavirus disease 2019 (COVID-19) vaccine brands have been used in Korea’s national immunization program. The Korea Disease Control and Prevention Agency has enhanced vaccine safety monitoring through a passive web-based reporting ...
Yeon-Kyeng Lee+10 more
doaj +1 more source
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
New England Journal of Medicine, 2021Background As mass vaccination campaigns against coronavirus disease 2019 (Covid-19) commence worldwide, vaccine effectiveness needs to be assessed for a range of outcomes across diverse populations in a noncontrolled setting.
N. Dagan+9 more
semanticscholar +1 more source
Physicians Infrequently Adhere to Hepatitis Vaccination Guidelines for Chronic Liver Disease [PDF]
, 2013Background and Goals:Hepatitis A (HAV) and hepatitis B (HBV) vaccination in patients with chronic liver disease is an accepted standard of care. We determined HAV and HBV vaccination rates in a tertiary care referral hepatology clinic and the impact of ...
A Wasley+27 more
core +8 more sources
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
New England Journal of Medicine, 2021Background Several cases of unusual thrombotic events and thrombocytopenia have developed after vaccination with the recombinant adenoviral vector encoding the spike protein antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (ChAdOx1
A. Greinacher+5 more
semanticscholar +1 more source
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
New England Journal of Medicine, 2021Summary We report findings in five patients who presented with venous thrombosis and thrombocytopenia 7 to 10 days after receiving the first dose of the ChAdOx1 nCoV-19 adenoviral vector vaccine against coronavirus disease 2019 (Covid-19).
N. H. Schultz+10 more
semanticscholar +1 more source
Vaccine hesitancy poses serious challenges for achieving coverage for population immunity. It is necessary to achieve high COVID‐19 vaccination acceptance rates and medical students’ coverage as future health care providers.
Shimaa M. Saied+3 more
semanticscholar +1 more source